Llwytho...
HDAC inhibitors enhance the immunotherapy response of melanoma cells
We focused on the ability of the pan-histone deacetylase (HDAC) inhibitors AR42 and sodium valproate to alter the immunogenicity of melanoma cells. Treatment of melanoma cells with HDAC inhibitors rapidly reduced the expression of multiple HDAC proteins as well as the levels of PD-L1, PD-L2 and ODC,...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncotarget |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Impact Journals LLC
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5669957/ https://ncbi.nlm.nih.gov/pubmed/29137331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17950 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|